Legal Representation
Attorney
BRIAN E. TURUNG
USPTO Deadlines 2 active 2 overdue
Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
---|---|---|---|---|---|
OPPOSITION
Notice of Publication |
NPUB | Apr 05, 2018 | 2650 days overdue | Medium | Until May 05, 2018 |
ITU SOU
Notice of Allowance Mailed - SOU Required |
NOAM | Nov 01, 2018 | 2440 days overdue | High | Until May 01, 2019 |
Application History
50 eventsDate | Code | Type | Description |
---|---|---|---|
Jan 2, 2025 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
Jan 2, 2025 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
Dec 31, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
Jul 31, 2024 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
Jul 31, 2023 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
Feb 15, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Nov 22, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Nov 22, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Nov 22, 2020 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
Nov 22, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Nov 22, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Nov 22, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Jan 30, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Jul 31, 2018 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Jun 26, 2018 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
Jun 25, 2018 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
May 31, 2018 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
May 31, 2018 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
May 9, 2018 | IUAF | S | USE AMENDMENT FILED |
May 9, 2018 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
May 1, 2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Mar 6, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Mar 6, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
Feb 14, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Jan 31, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Nov 4, 2017 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Nov 4, 2017 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
Nov 4, 2017 | CNSL | R | SUSPENSION LETTER WRITTEN |
Oct 17, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Oct 17, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Oct 16, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Sep 25, 2017 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Sep 25, 2017 | GNRT | O | NON-FINAL ACTION E-MAILED |
Sep 25, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN |
Sep 25, 2017 | RMRF | Z | REMOVE FROM TEASRF |
Aug 30, 2017 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED |
Aug 30, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Aug 28, 2017 | ALIE | A | ASSIGNED TO LIE |
Aug 8, 2017 | I | PAPER RECEIVED | |
Jul 17, 2017 | CNSL | R | SUSPENSION LETTER WRITTEN |
Jul 17, 2017 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Jul 17, 2017 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
Jun 21, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Jun 20, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Jun 20, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Mar 27, 2017 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Mar 27, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN |
Mar 27, 2017 | GNRT | F | NON-FINAL ACTION E-MAILED |
Mar 21, 2017 | DOCK | D | ASSIGNED TO EXAMINER |
Dec 28, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome
First Use Anywhere:
Mar 1, 2017
First Use in Commerce:
Mar 1, 2017
Classification
International Classes
005